MacroGenics shares surge 10.88% premarket after securing $75M partnership proceeds and realigning pipeline focus to ovarian cancer.

MacroGenics (MGNX) surged 10.88% in premarket trading following the release of Q3 2025 financial results and strategic updates. The company reported net income of $16.8 million ($0.27 per share), exceeding the Zacks consensus estimate of a $0.48 loss, with revenue of $72.8 million surpassing expectations. Key drivers included $75 million in non-dilutive partnership proceeds from Sanofi and Gilead, extended collaboration with Gilead on a novel T-cell engager platform, and a realigned pipeline prioritizing ovarian cancer development for lorigerlimab. The cash runway was extended into late 2027, and ADC programs (MGC026, MGC028, MGC030) advanced, including Phase 1 expansions. These developments signaled improved financial stability, strategic focus, and pipeline progress, bolstering investor confidence in the company’s long-term prospects.